These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31896113)

  • 1. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.
    Wang Z; Zheng C; Sun H; Yao W; Li K; Ma Y; Zheng S
    Dermatology; 2020; 236(3):262-270. PubMed ID: 31896113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
    Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin induces autophagy and apoptosis in Kaposiform hemangioendothelioma primary cells in vitro.
    Wang Z; Han Q; Wang J; Yao W; Wang L; Li K
    J Pediatr Surg; 2022 Jul; 57(7):1274-1280. PubMed ID: 35428493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression Prox1 in HemECs resembles Kaposiform hemangioendothelioma and cytotoxicity of sirolimus in vitro.
    Wang J; Han Q; Yan H; Yao W; Wang Z; Li K
    J Pediatr Surg; 2021 Jul; 56(7):1203-1210. PubMed ID: 33865602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
    Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
    J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
    Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
    Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
    Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
    Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
    Wang H; Guo X; Duan Y; Zheng B; Gao Y
    Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma.
    Zhang X; Yang K; Chen S; Ji Y
    J Dermatol; 2019 Oct; 46(10):898-901. PubMed ID: 31373046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angioma.
    Gong X; Ying H; Zhang Z; Wang L; Li J; Ding A; Zhou L; Lin X; Xiong P
    J Dermatol; 2019 Oct; 46(10):835-842. PubMed ID: 31373042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
    Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
    Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
    Yao W; Li K; Wang Z; Dong K; Zheng S
    Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mTOR pathway expression in lymphatic malformation and related diseases.
    Hori Y; Ozeki M; Hirose K; Matsuoka K; Matsui T; Kohara M; Tahara S; Toyosawa S; Fukao T; Morii E
    Pathol Int; 2020 Jun; 70(6):323-329. PubMed ID: 32067331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
    Chiu YE; Drolet BA; Blei F; Carcao M; Fangusaro J; Kelly ME; Krol A; Lofgren S; Mancini AJ; Metry DW; Recht M; Silverman RA; Tom WL; Pope E
    Pediatr Blood Cancer; 2012 Nov; 59(5):934-8. PubMed ID: 22648868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
    Kai L; Wang Z; Yao W; Dong K; Xiao X
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
    Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
    Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
    Ji Y; Chen S; Yang K; Xia C; Peng S
    J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaposiform hemangioendothelioma: current knowledge and future perspectives.
    Ji Y; Chen S; Yang K; Xia C; Li L
    Orphanet J Rare Dis; 2020 Feb; 15(1):39. PubMed ID: 32014025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review.
    Maza-Morales M; Valdés-Loperena S; Durán-McKinster LC; García-Romero MT
    Pediatr Dermatol; 2023; 40(3):440-445. PubMed ID: 36716766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
    Boscolo E; Pastura P; Glaser K; Goines J; Hammill AM; Adams DM; Dickie P; Hsi Dickie B; Le Cras TD
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27790. PubMed ID: 31045327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.